Kalpesh Patel, Principal Medical Science Liaison – Precision Oncology, shared on LinkedIn:
“Everyone’s posting about Tempus AI buying Personalis, Inc. today. But while many are stuck on the price tag, the real story is that this is the fifth MRD buyout in under a year.
- Natera / Foresight, up to $450M
- Roche / Saga Dx, ~$595M
- CareDx / Naveris, up to $260M
- Abbott / Exact Sciences
- Tempus / Personalis, ~$1.5B, roughly 19x revenue, all stock
The ctDNA players buying each other for scale (Natera, Tempus, CareDx), and the legacy IVD giants buying their way in (Roche, Abbott).
Why MRD? Because it’s the rare oncology test that isn’t one and done. Recurring surveillance, expanding Medicare coverage, and longitudinal data that feeds biopharma and the AI layer everyone’s building. Repeatable, and reimbursed revenue.
However, the P&Ls are not there yet. Personalis is guiding to a ~$105M net loss this year on 15-20% gross margin. Tempus is paying ~19x revenue for that, in stock, while its own shares dropped ~8% on the news. Per SEC filing, the deal even lets Personalis walk if Tempus trades under $46. It closed near $48 today.
MRD is going to be one of the defining categories in oncology diagnostics. But we are watching a field where the science is moving faster than the balance sheets, and strategic buyers are paying up anyway. The financials are still catching up.”
Other articles about MRD on OncoDaily.